Big Biologics Bet: China’s Innovent Gets $100m Financing
This article was originally published in PharmAsia News
A record-breaking private financing for a Chinese biotech has seen bets placed on Suzhou-based Innovent Bio, which has 10 monoclonal antibodies including four biosimilars in its pipeline.
You may also be interested in...
Throughout 2020, China’s drive to introduce more and newer drugs to the market did not slow but was rather accelerated by the COVID-19 pandemic. But can people afford them?
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.